Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Sees New OTC Drug Law Spurring ‘Switch’ Production

This article was originally published in PharmAsia News

Executive Summary

The effort by Japan's Ministry of Health to encourage more production of over-the-counter "switch drugs" appears to be bearing fruit. Drug makers are racing to release their versions of the drugs and help revive the OTC market in Japan. New laws take effect next June that classify OTC drugs into three groups based on their efficacy and risk of side effects. The "switch drugs" would require a pharmacist to explain how the drugs for lifestyle ailments are to be used. That provision is expected to eliminate pharmacy competition by most discount retailers, so manufacturers are focusing first on that sector of medicines. (Click here for more - a subscription may be required

You may also be interested in...

Japan’s OTC Drug Industry Releases 20 Compounds For Switch OTC Drugs

TOKYO - Japan's self-medication drug industry, responding to MHLW's new policies to encourage over-the-counter drug use, is stepping up efforts to launch over-the-counter pharmaceuticals by unveiling 20 additional chemical composites

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts